BCL2L1 and neoplasm: Early studies positively and negatively correlated response to venetoclax to Bcl-2 and Bcl-xL or Mcl-1 protein expression, respectively, and to mitochondrial priming by BH3 mimetic peptides ex vivo in tumor cells [4,6].